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Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumours. Dysadherin, recently
characterised by members of our research team, has an anti-cell–cell adhesion function and downregulates E-cadherin in a post-
transcriptional manner. The aim of the present study was to study the role of dysadherin in breast cancer progression, in association
with the E-cadherin expression and the histological type. We have selected ductal carcinoma, which is by far the most common type
and lobular carcinoma, which has a distinctive microscopic appearance. Dysadherin and E-cadherin expression was examined
immunohistochemically in 70 invasive ductal carcinomas, no special type (NST), and 30 invasive lobular carcinomas, with their
adjacent in situ components. In ductal as well as in lobular carcinoma dysadherin was expressed only in the invasive and not in the in
situ component, and this expression was independent of the E-cadherin expression. Specifically, all 10 (100%) Grade 1, 37out of
45(82.2%) Grade 2 and six out of 15 (40%) Grade 3 invasive ductal carcinomas showed preserved E-cadherin expression, while
‘positive dysadherin expression’ was found in six out of 10 (60%) Grade 1, 34 out of 45(75.5%) Grade 2 and all 15 (100%) Grade 3
neoplasms. None of the 30 infiltrating lobular carcinomas showed preserved E-cadherin expression, while all the 30 infiltrating lobular
carcinomas exhibited ‘positive dysadherin expression’. Dysadherin may play an important role in breast cancer progression by
promoting invasion and, particularly in lobular carcinomas, it might also be used as a marker of invasion.
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Recent advances into molecular pathology of breast cancer have
refined diagnostic accuracy and classification systems of the most
common malignant neoplasm of women, rendering personalised
therapy more possible. Today, there is a plethora of molecular
genetic data that indicate differences in pathogenesis between the
various types of breast carcinomas and thus support their
categorisation, to the patient benefit. The demonstration of lack
of E-cadherin expression in lobular neoplasms has had a sound
impact with practical applications (Mastracci et al, 2005) In about
half of lobular carcinomas, loss of E-cadherin involves genetic
changes, that is loss of heterozygosity (LOH) at 16q22.1, while in
the other half epigenetic events are involved (Knudsen and
Wheelock, 2005; Mastracci et al, 2005). Ductal carcinomas, on
the other hand, express E-cadherin, albeit in reduced levels and/or
in abnormal cellular locations (Knudsen and Wheelock, 2005).
Reduction/loss of E-cadherin has been associated with the
development and progression of many epithelial neoplasms.
Aberrant E-cadherin expression (heterogeneous, cytoplasmic, or
absent) has been detected immunohistochemically in several
cancers, including head and neck carcinoma, gastric adeno-
carcinoma, lobular breast carcinoma, lung cancer, colorectal
carcinoma, prostate adenocarcinoma, pancreatic, and bladder
cancer (Becker et al, 1994; Hirohashi, 1998; Chang et al, 2002;
Charalabopoulos et al, 2002, 2004; Hirohashi and Kanai, 2003;
Mastracci et al, 2005; Massarelli et al, 2005). In the vast majority of
these neoplasms such expression has been associated with poor
differentiation, increased metastatic potential and poor prognosis.
In breast the scenario is more complicated, since lobular
carcinoma, that typically does not express E-cadherin has a more
favourable outcome than ductal carcinoma, which in general
expresses E-cadherin. Furthermore, there are contradictory data
on the possible association between E-cadherin expression and
high-grade tumours with increased metastatic potential (Oka et al,
1993; Charpin et al, 1997; Heimann et al, 2000; Gillett et al, 2001;
Parker et al, 2001; Elzagheid et al, 2002; Gupta et al, 2003; Knudsen
and Wheelock, 2005; Rakha et al, 2005). It is clear that there are
pieces missing from the puzzle of adhesion molecules and breast
carcinoma.
Recently, the cloning and characterisation of dysadherin
(FXYD5), a cell membrane glycoprotein that has an anti-cell–cell
adhesion function and downregulates E-cadherin in a post-
transcriptional manner has been reported, by members of our
research team. This novel cancer-associated protein has been
detected in head and neck, tongue, oesophageal, gastric, colorectal,
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stesticular, pancreatic, thyroid, and cervical carcinomas as well as
in malignant melanoma and has been associated with tumour
aggressiveness (Ino et al, 2002; Tsuiji et al, 2002; Aoki et al, 2003;
Sato et al, 2003; Shimamura et al, 2003, 2004; Nakanishi et al, 2004;
Shimada et al, 2004a,b; Wu et al, 2004; Batistatou et al, 2005;
Nishizawa et al, 2005; Batistatou et al, 2006; Kyzas et al, 2006).
A recent in vitro study has demonstrated that dysadherin has
prometastatic effects that are independent of E-cadherin expres-
sion (Nam et al, 2006). The aim of the present study was to
investigate further the expression of dysadherin in breast
carcinoma, with particular emphasis to the acquisition of a lobular
or a ductal phenotype, in combination with E-cadherin expression.
MATERIALS AND METHODS
One hundred formalin-fixed, paraffin-embedded archival tissue
blocks of breast carcinomas were included in the current study and
represented an equal number of female patients (mean age 54.5
years, range 35–79). The material consisted of 70 invasive ductal
carcinomas, no special type, NST (10 Grade 1, 45 Grade 2 and 15
Grade 3, graded using the modified Bloom and Richardson
method), in 30 of which an adjacent in situ ductal carcinoma
was identified, and 30 invasive lobular carcinomas, in 15 of which
an adjacent in situ lobular carcinoma was identified.
Immunohistochemistry
We performed immunostaining on formalin-fixed, paraffin-
embedded tissue sections using the EnVision System (DAKO
Corp., Netherlands), and the monoclonal antibodies: NCC-M53
against dysadherin and E-cadherin (CM170B, Biocare Medical, CA,
USA). Briefly, 4-mm-thick tissue sections were deparaffinised in
xylene; rehydrated through graded concentrations of alcohol and
heated in a microwave oven for two cycles of 15min each at 300W,
in citrate buffer, for antigen retrieval. Endogenous peroxidase
activity was blocked with H2O2 solution in methanol (0.01 M), for
30min. After washing with phosphate-buffered saline (PBS) for
5min, the primary antibodies NCC-M53 (dilution 1:1000) and
CM170B (dilution 1:50) were applied for incubation (30min at
room temperature and overnight at 41C respectively). Then the
slides were washed for 10min with PBS and were visualised with
the EnVision system using diaminobezidine tetrahydrochloride as
a chromogen. Finally, all sections were counterstained with
haematoxylin. Positive staining of endothelial cells and lympho-
cytes was used as an internal positive control for dysadherin. As an
internal positive control for E-cadherin, positive staining of non
neoplastic ductal epithelial cells was used. As a negative control the
first antibody was substituted with normal mouse immunoglobulin
of the same class.
Evaluation of the staining
For each sample, at least 1000 neoplastic cells were counted, and
the percentage of cancer cells with positive membranous
immunostaining as well as the staining intensity were recorded.
For the purposes of statistical analysis, as described previously
(Shimada et al, 2004b; Batistatou et al, 2005), when more than
50% of tumour cells were stained for dysadherin, the tumour was
evaluated as ‘positive dysadherin expression (Dys(þ))’. When less
than 50% of tumour cells were stained for dysadherin, the tumour
was evaluated as ‘negative dysadherin expression (Dys( ))’.
Regarding E-cadherin, when more than 50% of tumour cells
showed complete membranous staining, the tumour was evaluated
as ‘preserved E-cadherin expression (E-cad(þ))’, while when less
than 50% of tumour cells were positive, the tumour was evaluated
as ‘reduced E-cadherin expression (E-cad( ))’. Cytoplasmic
immunostaining was considered as aberrant expression and was
not included in the immunopositive cases.
Statistical analysis
Analyses were conducted in SPSS software version 11.0 (SPSS,
Inc, Chicago, IL, USA). For comparisons between antibodies’
expression with clinicopathological variables we used the w
2 test.
The level of statistical significance was Po0.05.
RESULTS
Ductal carcinoma
Membranous E-cadherin expression was detected in epithelial cells
of non-neoplastic ducts and acini and this served as internal
positive control. In neoplastic cells there was some variation in
distribution, depending on the grade and the pattern of stroma
infiltration. Specifically, all 10 (100%) Grade 1, 37 out of 45
(82.2%) Grade 2 and six out of 15 (40%) Grade 3 neoplasms
showed preserved E-cadherin expression (Table 1, Figure 1A). In
immunopositive Grade 2 and Grade 3 tumours the expression of E-
cadherin was more heterogeneous, with variations in intensity and
distribution of positive cells. Thus, cells in clusters or in tubular
structures exhibited higher percentage and more intense membra-
nous staining than individual cells infiltrating the stroma. In the
periphery of the invasive ductal carcinoma an intraductal
component was observed in several cases. In this in situ ductal
component the expression of E-cadherin was similar to the non-
neoplastic epithelial cells, homogeneous and stronger that the
adjacent invasive component (Figure 1B).
Dysadherin expression was detected in myoepithelial cells of
ducts and acini, but not in non-neoplastic epithelial cells, as well as
in endothelial cells of vessels and lymphocytes, as described
previously (Batistatou et al, 2005, 2006). Dysadherin immuno-
staining was observed in the membranes of the neoplastic cells and
it was heterogeneous throughout the neoplasm (Figure 1C).
In particular, preferential expression in diffuse than in compact
infiltrative areas was detected. Overall, ‘positive dysadherin
expression’ was found in six out of 10 (60%) Grade 1, 34 out of
45 (75.5%) Grade 2 and all 15 (100%) Grade 3 neoplasms (Table 1,
Figure 1B). Interestingly, in the adjacent in situ ductal carcinoma a
small proportion of neoplastic cells (o10%) exhibited membra-
nous immunostaining for dysadherin (Figure 1D). Dysadherin
expression was not correlated with E-cadherin expression in IDC
(P40.05).
Lobular carcinoma
None of the 30 infiltrating lobular carcinomas showed preserved
E-cadherin expression (Table 1, Figure 2A). The vast majority
Table 1 E-cadherin and dysadherin expression in invasive breast
carcinomas
Histologic type
Preserved
E-cadherin
expression
‘Positive’
dysadherin
expression
Invasive ductal carcinoma
Grade 1 (10) 10 (100 %) 6 (60%)
Grade 2 (45) 37 (82.2%) 34 (75.5%)
Grade 3 (15) 6 (40%) 15 (100%)
Total (70) 53 (75.7%) 55 (78.6%)
Invasive lobular carcinoma
Total (30) 0 (0%) 30 (100%)
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swas completely negative, while only in two of them, o20% of
neoplastic cells showed weak membranous and cytoplasmic
immunopositivity. Interestingly, the adjacent in situ lobular
carcinoma was completely negative, as well (Figure 2B).
All the 30 infiltrating lobular carcinomas exhibited ‘positive
dysadherin expression’ (Figure 2C). In this in situ lobular
component the expression of dysadherin was limited to a small
proportion (o10%) of neoplastic cells (Figure 2D).
DISCUSSION
Two of the most important characteristics of neoplastic cells
are their abilities to grow locally and to metastasise. For both
of these processes tumour cells must initially dissociate from
each other, either singly or in small nests and invade the
surrounding stroma. Today it is generally accepted that at least
for carcinomas, adhesion molecules, in particular E-cadherin,
AB
D C
Figure 1 A case of invasive ductal carcinoma, grade II, with adjacent in situ component. (A) E-cadherin expression is significantly reduced in invasive ductal
carcinoma (DABX400). (B) Membranous expression of E-cadherin is retained in the adjacent in situ component (DABX400). (C) Strong, membranous
expression of dysadherin is evident in invasive ductal carcinoma (DABX400). (D) Dysadherin is not expressed in the adjacent in situ component
(DABX400).
AB
D C
Figure 2 A case of invasive lobular carcinoma, with adjacent in situ component. (A) E-cadherin expression is lost in invasive lobular carcinoma
(DABX400). (B) E-cadherin expression is lost in the adjacent in situ component (DABX400). (C) Membranous expression of dysadherin is evident in
invasive lobular carcinoma, (DABX400). (D) Dysadherin is not expressed in the adjacent in situ component, in contrast with the infiltrating tumour
(DABX400).
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splay a pivotal role in this process by being downregulated (Hirohashi,
1998; Charalabopoulos et al, 2002; Hirohashi and Kanai, 2003). In
general, there is an association between aberrant E-cadherin
expression, tumour dedifferentiation and poor clinical outcome.
Regarding breast cancer, E-cadherin expression varies depen-
ding on the histological subtype. Thus, in ductal carcinoma
E-cadherin is expressed, albeit in reduced levels and aberrant
cellular locations. Although E-cadherin correlates inversely with
the grade of the tumour, reduced E-cadherin expression is not
adequate to predict clinical outcome and there are contradictory
studies on the association between E-cadherin and survival
(Knudsen and Wheelock, 2005). Moreover, it has been reported
that in other breast cancers with known poor prognosis, such as
inflammatory breast cancer, there is overexpression of E-cadherin
(Knudsen and Wheelock, 2005). An interesting concept is that
possibly the reduction of E-cadherin expression in breast
carcinomas, other than lobular, is transient, due to epigenetic
modifications. Several mechanisms for reversible reduction of E-
cadherin expression in human neoplasms have been reported
(Hirohashi, 1998; Charalabopoulos et al, 2002; Hirohashi and
Kanai, 2003). Among them, recently, a novel cell membrane
glycoprotein named ‘dysadherin’ (from the Greek prothema dys-,
which means difficulty, or aberration, or reversibility) has been
shown to downregulate E-cadherin in a post-transcriptional
manner and reduce cell–cell adhesiveness in in vitro studies and
in animal models. Dysadherin is a member of the FXYD family
(FXYD5 or Related to Ion Channel). It is located at chromosome 19
and has a single transmembrane domain. It interacts with and
modulates the properties of the Na
þ,K
þ ATPase (Ino et al, 2002;
Lubarski et al, 2005). In human tissues increased dysadherin
expression has been correlated with the development of metastasis
and poor prognosis in gastric, pancreatic, colorectal, oesophageal,
thyroid, tongue and cervical carcinomas, as well as in malignant
melanoma (Aoki et al, 2003; Sato et al, 2003; Shimamura et al,
2003, 2004; Nakanishi et al, 2004; Shimada et al, 2004a,b; Wu et al,
2004; Batistatou et al, 2005, 2006; Nishizawa et al, 2005; Kyzas et al,
2006). Furthermore, in a small pilot series of breast cancer patients,
dysadherin expression was correlated with poor prognosis (Ino et al,
2002). In most of these neoplasms, as well as in testicular tumours
and lymph node metastases of colorectal adenocarcinoma, increased
dysadherin expression was correlated with reduced E-cadherin
expression (Aoki et al,2 0 0 3 ;S a t oet al, 2003; Shimamura et al,
2003, 2004; Wu et al,2 0 0 4 ;B a t i s t a t o uet al, 2005, 2006). In invasive
ductal carcinoma, as reported in this study, there is an increase in
dysadherin expression, which is not related to E-cadherin expression.
This lack of association has also been reported in pancreatic, primary
colorectal and gastric carcinomas (Shimamura et al, 2003; Shimada
et al, 2004b; Batistatou et al, 2005). Furthermore, in the in situ
ductal carcinoma dysadherin was not expressed. On the basis of
these data we would like to propose that in ductal carcinomas,
dysadherin can promote invasion independently of the E-cadherin
expression.
Lobular breast carcinomas, typically exhibit loss of E-cadherin
expression, but they tend to have a more favourable clinical
outcome than the more common ductal carcinomas. This loss is an
early event affecting not only lobular carcinoma in situ but even
atypical lobular neoplasia (Mastracci et al, 2005). This silencing of
E-cadherin is attributed to genetic as well as epigenetic events
(Knudsen and Wheelock, 2005; Mastracci et al, 2005). In
approximately 50% of lobular carcinomas loss of E-cadherin
involves LOH at the chromosomal region of 16q, which includes
the E-cadherin gene CDH1 locus and mutations in the remaining
allele (Kanai et al, 1994; Vos et al, 1997; Huiping et al, 1999;
Knudsen and Wheelock, 2005; Mastracci et al, 2005). This LOH
definitely accompanies mutations in cases of invasive lobular
carcinoma, however, the classic pattern of LOH coupled with
inactivating mutations in lobular carcinoma in situ has not been
confirmed. In the other 50% loss of E-cadherin is attributed to
epigenetic events, with hypermethylation of the E-cadherin
promoter region at CpG islands being one of the most important
ones and possibly occurring very early, even at the stage of atypical
lobular hyperplasia (Sarrio et al, 2004; Shibata et al, 2004; Knudsen
and Wheelock, 2005; Mastracci et al, 2005).
In this study we have confirmed the loss of E-cadherin
expression, in in situ and invasive breast carcinoma. On the basis
of the rare expression of dysadherin in lobular carcinoma in situ
we can conclude that dysadherin is not responsible for E-cadherin
downregulation in lobular carcinoma. An interesting finding from
our study is the difference in dysadherin expression between
in situ and invasive lobular carcinoma. In breast carcinoma the
progression from in situ to invasive disease is not clearly defined
and the specific events that mark the transition to an invasive
tumour are under intense investigation. Lack of E-cadherin
expression cannot be associated with an invasive phenotype, since
it is also evident in the in situ component. On the other hand,
we have shown that dysadherin is specifically and constantly
expressed in invasive lobular carcinomas. On the basis of this
finding we propose that dysadherin is a possible causative player
in the process of acquiring an invasive phenotype, as well as a
possible marker for invasiveness. It has also been proposed that
loss of E-cadherin expression is responsible for the distinct pattern
of invasion observed in lobular neoplasms (Knudsen and Wheelock,
2005; Mastracci et al, 2005). We would like to add that another
major contributor to this characteristic invasion pattern, with
single cells arranged in cords is the expression of dysadherin. The
latter possibly acts, either alone or in conjunction with loss of
E-cadherin, by allowing cells to dissociate from each other. Studies
on the function of dysadherin are available by experimental data,
where dysadherin appears to play an important role in neoplastic
cell invasion and metastasis (Ino et al, 2002; Nam et al, 2006).
The exact molecular mechanisms of these effects have not
been elucidated yet. Recently, it has been shown that, besides
downregulating E-cadherin, dysadherin can promote invasion at
least in breast cancer cells in vitro, through an E-cadherin-
independent mechanism. This mechanism involves enhanced
signaling through the NF-kB pathway, which leads to increased
production of the tumour-promoting (C-C motif) ligand 2 (CCL2)
(Nam et al, 2006).
In conclusion, in this study we have investigated the role of
specific adhesion/dysadhesion molecules in the development of
breast carcinoma. We have selected ductal carcinoma which is by
far the most common type, and lobular carcinoma which has a
distinctive microscopic appearance. We have shown similarities
and differences between these two types. Interestingly, in ductal as
well as in lobular carcinoma, dysadherin was expressed only in the
invasive and not in the in situ component, and this expression was
independent of E-cadherin. Thus, dysadherin may play an
important role in breast cancer progression by promoting invasion
and, particularly in lobular carcinomas, it might also be used as a
marker of invasion.
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